PharmaDossierIndependent biopharma information, guidance, and source-cited analysis.

Topic

Obesity

Obesity drug access, GLP-1 and multi-mechanism coverage, payer restrictions, step therapy, and the evolving formulary landscape for weight management.

1 article·Lives underPricing & Access Commercialization·Last updated 2026-05-26

Pipeline· May 26, 2026 · 8 min read

CagriSema (cagrilintide/semaglutide): pre-approval evidence, REDEFINE trial results, and what access teams should expect

By Ran Chen#GLP-1 #Amylin Analog #Obesity